Solon Eiendom ASA

Solon Eiendom is a biotechnology company. Co.'s focus is the research and development of peptide based vaccines against viral diseases, primarily human immunodeficiency virus (HIV). As of Dec 31 2013, Co.'s clinical development pipeline comprised of two vaccine candidates for the treatment of HIV, Vacc-4X and Vacc-C5. Vacc-4X is being investigated in two phases II trials in collaboration with Celgene Inc.
  • TickerSOLON
  • ISINNO0003106700
  • ExchangeOslo Bors
  • SectorPharmaceuticals & Biotechnology
  • CountryNorway
Simen Mortensen

Covid-19 fallout only delayed

We expect still-limited direct Covid-19 effects in P&Ls for the Nordic construction names in Q2. However, as a late-cycle sector, we are concerned about a pandemic aftershock, and do not believe public sector spending will offset slower newbuild sales and lower private sector demand beyond 2020. Valuations of some of the names we cover look rich, but we maintain a neutral sector view. NRC and Bonava remain our top sector picks.

Håkon Astrup ...
  • Niclas Gehin
  • Ole-Andreas Krohn
  • Simen Mortensen
  • Tomi Railo

Northern Lights

André Thormann ...
  • Bengt Jonassen
  • Daniel Thorsson
  • Jonas Bru Lien
  • Petter Nystrøm

Talking Points - Construction & Real Est.: Norway Q2’20 previews

Dustin (Hold) Preview: Finally seeing positive estimate revisions SBO and SOLON down to HOLD We favour AFG, VEI and ENTRA

Bengt Jonassen ...
  • Daniel Vårdal Haugland
  • Tobias Kaj

Sector Report - Norway Q2’20 previews

Q2e: revenues of NOK 6,844m, PTP of NOK 339m High quality company with zero net debt Valuation: P/E of ~16x on normalised EPS

Bengt Jonassen ...
  • Daniel Vårdal Haugland

Solon Eiendom - Taking a breather

Q2e: EBIT of NOK 25m Current volume and margin assumptions are too high Resetting expectations: ’21e-‘22e EBIT down ~28%

Solon Eiendom ASA: 1 director bought

A director at Solon Eiendom ASA bought 13,000 shares at 28.609NOK and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of ...

Simen Mortensen

Covid-19 fallout only delayed

We expect still-limited direct Covid-19 effects in P&Ls for the Nordic construction names in Q2. However, as a late-cycle sector, we are concerned about a pandemic aftershock, and do not believe public sector spending will offset slower newbuild sales and lower private sector demand beyond 2020. Valuations of some of the names we cover look rich, but we maintain a neutral sector view. NRC and Bonava remain our top sector picks.

André Thormann ...
  • Bengt Jonassen
  • Daniel Thorsson
  • Jonas Bru Lien
  • Petter Nystrøm

Talking Points - Construction & Real Est.: Norway Q2’20 previews

Dustin (Hold) Preview: Finally seeing positive estimate revisions SBO and SOLON down to HOLD We favour AFG, VEI and ENTRA

Bengt Jonassen ...
  • Daniel Vårdal Haugland
  • Tobias Kaj

Sector Report - Norway Q2’20 previews

Q2e: revenues of NOK 6,844m, PTP of NOK 339m High quality company with zero net debt Valuation: P/E of ~16x on normalised EPS

Bengt Jonassen ...
  • Daniel Vårdal Haugland

Solon Eiendom - Taking a breather

Q2e: EBIT of NOK 25m Current volume and margin assumptions are too high Resetting expectations: ’21e-‘22e EBIT down ~28%

Simen Mortensen

Solon Eiendom (Hold, TP: NOK32.00) - Strong sales in Q2

Despite the Covid-19 lockdown, Solon Eiendom managed to sell 90 homes, with good sales late Q2, beating our forecasts. As a result, we have raised our 2021–2022e EPS, expecting ramped up housing starts in the coming quarters. Ahead of the Q2 results (due at 08:00 CET on 26 August), we forecast EBIT EBIT of NOK67m. We have lifted our target price to NOK32 (27) on our updated forecasts and peer valuations, but reiterate our HOLD as the valuation seems fair versus peers.

Håkon Astrup ...
  • Niclas Gehin
  • Ole-Andreas Krohn
  • Simen Mortensen
  • Tomi Railo

Northern Lights

Nicolay Dyvik ...
  • Ole-Andreas Krohn
  • Simen Mortensen
  • Stefan Gauffin

Northern Lights

Alexander Aukner ...
  • Jon Masdal
  • Marius Knudssøn
  • Martin Huseby Karlsen
  • Nicolay Dyvik
  • Ole Martin Westgaard
  • Ole-Andreas Krohn
  • Simen Mortensen
  • Stefan Gauffin

Northern Lights

Alexander Aukner ...
  • Eivind Sars Veddeng
  • Joachim Gunell
  • Karl-Johan Bonnevier
  • Ole Martin Westgaard
  • Ole-Andreas Krohn
  • Simen Mortensen

Northern Lights

Eivind Sars Veddeng ...
  • Håkon Astrup
  • Jesper Ingildsen
  • Jimi Lehtonen
  • Jon Berggren
  • Marius Knudssøn
  • Martin Huseby Karlsen
  • Nicolai Farstad Olsen
  • Nicolay Dyvik
  • Ole Martin Westgaard
  • Ole-Andreas Krohn
  • Rune Majlund Dahl
  • Simen Mortensen

Northern Lights

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch